research use only
Cat.No.S6466
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Fatty Acid Synthase Inhibitors | Denifanstat (TVB-2640) Fatostatin TVB-3664 C75 Betulin FT113 C75 trans Desoxyrhaponticin Praeruptorin B Sodium palmitate |
| Molecular Weight | 330.50 | Formula | C22H34O2 |
Storage (From the date of receipt) | 2 years -20°C liquid |
|---|---|---|---|---|---|
| CAS No. | 86227-47-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | AMR101, EPA ethyl ester, Ethyl eicosapentaenoate | Smiles | CCOC(=O)CCC\C=C/C/C=C\C\C=C/C/C=C\C\C=C/CC | ||
|
In vitro |
|
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
Triglyceride
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04216251 | Completed | Colorectal Adenoma|Colorectal Cancer|Endoscopic Surgery|Eicosapentaenoic Acid|Gastrointestinal Microbiome |
Massachusetts General Hospital|National Institutes of Health (NIH) |
December 9 2020 | Phase 1|Phase 2 |
| NCT03661047 | Withdrawn | Colon Cancer |
Massachusetts General Hospital|Harvard School of Public Health (HSPH) |
November 30 2019 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.